Based on evidence from many randomized controlled trials, the current mainstay treatment for neovascular age-related macular degeneration (AMD) is intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection [1–7]. The gene discussed is VEGFA; the disease is age-related macular degeneration.